AIM2 and pulmonary fibrosis: The evidence suggests that activation of the inflammasome, especially the NLRP3 and AIM2 inflammasomes, contributes to pulmonary fibrosis; however, the molecular mechanisms associated with the AIM2 inflammasome and the utility of AIM2 inflammasome inhibitors as therapeutic agents in PF remain to be investigated.